New White Paper - Read AAM Report on Drug Shortages

Generic Supply Chain

Ensuring Patient Access to Amoxicillin When Demand is High

The Facts About the Generic Supply and Production of Antibiotics Used to Treat Flu, RSV and COVID

Families and physicians in certain parts of the country are finding it difficult to access commonly prescribed medicines, such as amoxicillin, this winter. The combination of widespread influenza, respiratory syncytial virus (RSV) and COVID infections – in what public health experts are calling a tripledemic – has led to unforeseen demand for these low-cost generic treatments.

A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain

With the right incentives, more essential medicines can be made in America. AAM has ideas for how to encourage this. Check out the 2nd edition of our AAM Blueprint to Enhance the Security of the U.S. Pharmaceutical Supply Chain to learn more:

Second Edition of AAM’s Blueprint to Enhance the Security of the U.S. Pharmaceutical Supply Chain

The U.S. health care system benefits from a globally diverse generic pharmaceutical supply chain. Despite concerns voiced by policymakers and pundits early in the pandemic, the generic pharmaceuticals supply chain has proven highly resilient. But this success does not decrease the value of increasing the number of essential medicines produced in the United States or the need for the U.S. government to incentivize the investments required to grow the generic pharmaceuticals manufacturing base.

AAM Calls for Increased Voluntary Licensing of Covid Vaccines to Increase Patient Access

WASHINGTON, D.C. (August 16, 2021) — AAM and its member companies have worked extremely hard to enhance patient access to affordable treatments throughout the COVID-19 pandemic. This includes manufacturing dexamethasone, which is estimated to have saved more than 1 million lives worldwide, and producing under voluntary licensing agreements leading vaccines and other therapeutics for use by patients in developing countries.

The Generics and Biosimilars Industry Has a Plan to Secure Our Medicines — #SecureOurMeds

The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to "#SecureOurMeds." We already produce billions of doses of medicine right here in America, and our plan ensures continued patient access through COVID and beyond.

Learn more about our path forward at:

Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines: Securing Sustainable Markets

This paper examines the challenges to market sustainability for generic and biosimilar medicines that have cleared the regulatory and patent hurdles to obtain FDA approval and launch into the U.S. market. It is the first in a series of AAM papers that will highlight challenges to the overall sustainability of the generics and biosimilars industry.

AAM Outlines Policy Solutions for Sustained Patient Access to Generic and Biosimilar Medicines

Association for Accessible Medicines Unveils Policy Agenda for
Biden Administration and 117th Congress
Outlines Policy Solutions to Support Long-Term Sustainability of Generic and Biosimilar Medicines

New Campaign Highlights Lifesaving Role Generic Drugs Have Played in Treatment of COVID-19
Report Series Examines Threats to Patient Access and Affordability

Subscribe to Generic Supply Chain

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.